Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose Vial, 25 Vials per Tray, Rx only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047. Vial NDC 63323-487-07, Tray NDC 63323-487-37
Published July 14, 2021 · Recall initiated: June 25, 2021
Summary
FDA records drug Class II recall D-0651-2021, published July 14, 2021 and initiated June 25, 2021. Recalling firm: Fresenius Kabi USA LLC; Status: Terminated; Reported quantity: 234,800 vials; Lot: Batch, expiry: Batch 6123435, exp 01/2022; 6124730, 6124731, exp 07/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Low out of specification results for epinephrine assay.
What to do
Voluntary: Firm initiated · Letter
Get an email if XYLOCAINE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- XYLOCAINE
- Manufacturer
- Fresenius Kabi USA LLC
- Distributor
- Distributed Nationwide in the USA
- UPC
- 0363323484576
- Lot
- Batch, expiry: Batch 6123435, exp 01/2022; 6124730, 6124731, exp 07/2022
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL,July 29, 2026
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL), 25 Multiple-Dose Vials, 50 mL,July 29, 2026
- FDA2% Xylocaine DENTAL with Epinephrine 1:100,000 (Lidocaine HCI and Epinephrine Injection USP), packaged in aDecember 24, 2025
- FDAXylocaine + Epinephrine, multi dose vial 2%, 20 mL, 25 count box, Rx only, MFG: Fresenius Kabi USA LLC, NDCJune 15, 2022
- FDABuprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film,July 14, 2021
- FDATopotecan Injection 4 mg/4mL (1 mg/mL), Single-Dose vial, Teva Pharmaceuticals USA, Inc. North Whales, PAJuly 14, 2021
Questions about this recall
Was Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose Vial, 25 Vials per Tray, Rx only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047. Vial NDC 63323-487-07, Tray NDC 63323-487-37 recalled?
Yes. FDA published recall D-0651-2021 on July 14, 2021. Reported hazard: Low out of specification results for epinephrine assay.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: XYLOCAINE. UPC: 0363323484576.